SXTP

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026: Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026. The Company achieved a gross profit of approximately $76 thousand in the first quarter of 2026, compared with a gross profit of approximately $90 thousand in the first quarter of 2025. Operating expenses were approximately $2.17 million in the first quarter of 2026, compared with approximately $2.09 million in the first quarter of 2025. Net loss attributable to common shareholders in the first quarter of 2026 was approximately $2.21 million, or a net loss of $1.28 per share, compared with a net loss of approximately $2.00 million, or a net loss of $6.25 per share, in the first quarter of 2025. About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine) in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of...

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025: Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns. The Company achieved a gross profit of approximately $223.8 thousand in 2025, compared with approximately $222.8 thousand in 2024. Gross profit remained relatively stable despite inventory write-offs associated with a final batch of short-dated product entering the supply chain. This charge was a necessary, non-recurring cost incurred as part of scaling operations. Operating expenses were approximately $8.4 million in 2025, compared with approximately $10.0 million in 2024. The decrease in Research and Development costs of $2.9 million was due to 2024 including $3.2 million of non-cash and non-recurring charges. The increase in general and administrative expenses of $1.3 million was driven primarily by $967.6 thousand in additional sales advisory, advertising and promotion expenses. Net loss attributable to common shareholders in 2025 was approximately $7.37 million, or $11.73 per share, compared with a net loss of approximately $7.96 million, or $74.17 per share, in 2024 — an improvement of approximately $590 thousand. This improvement was driven primarily by the absence of non-recurring, non-cash Research and Development charges that burdened fiscal year 2024, partially offset by higher selling expenses in fiscal year 2025 and a $1.4 million reduction in the favorable Change in Fair Value of Derivative Liabilities. Recent Business Highlights: As of March 30, 2026, the Company had 2,636,788 shares outstanding. In the 12 months through March 27, 2026 the Company had offered and sold approximately $4,026,722 in common shares using its At-the-Market facility, exhausting current baby shelf capacity. In March 2026, the Company announced that all patients enrolled in its expanded access study for relapsing babesiosis were cured...

Q3 2025 net product revenue increased 223% year-over-year to $438 thousand Gross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the third fiscal quarter of the 2025 year, ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025: ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes (Q3 2024) to 1,505 boxes (Q3 2025). The Company posted a gross loss of approximately $100 thousand in the third quarter of 2025, compared to an approximate gross profit of $24 thousand in the third quarter of 2024, due to a one-time inventory write-off associated with newly produced validation lots which will no longer be accepted by supply chain partners after the end of Q1 2026 due to limited remaining shelf-life. Additional lots with four-year shelf-life are currently in production and expected to fully enter the supply chain in early Q1 2026. Operating expenses were approximately $2.32 million in the third quarter of 2025, compared to approximately $2.16 million in the third quarter of 2024. The increase in expenses is primarily driven by the $367 thousand in additional advertising and sales promotion expenditures. Net loss attributable to common shareholders in the third quarter of 2025 was approximately $2.44 million, or ($0.66) per share, compared to approximately $2.27 million, or ($4.65) per share in the third quarter of 2024, representing an additional $171K in losses. Business Highlights for the Quarter Ended September 30, 2025: On July 14, 2025, we announced our intention to seek a Minor Use Minor Species (MUMS) designation from the United States Food and Drug Administration (FDA) for the treatment of acute canine babesiosis following a comprehensive gap analysis of our existing data. After completing a 6,000 patient nationwide survey and quantitative research study, we announced on July 15, 2025 that we had determined the total addressable market (TAM) for Babesiosis treatment to be up to $1.1 billion through patent expiration in 2035. On July 17, 2025, we announced our entry into a sponsored research agreement with Tulane University to evaluate activity of tafenoquine agai...

Revenue: US$307.9k (up 145% from 2Q 2024). Net loss: US$1.86m (loss narrowed by 57% from 2Q 2024). US$1.26 loss per share (improved from US$21.14 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 54% p.a. on average during the next 2 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 4.3% from a week ago. What about risks? Every company has them, and we've spotted 5 warning signs for 60 Degrees Pharmaceuticals (of which 3 are concerning!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 2025. While net product revenues declined compared to Q2 2024 due to a now resolved supply chain disruption, the Company reported an increase in profitability, largely attributed to cash-pay patients using KODATEF® (tafenoquine) 16-count boxes which were imported with U.S. Food and Drug Administration (FDA) consent to help mitigate a temporary disruption of supply of ARAKODA® 16-count boxes. Provided the Company reaches minimum enrollment in its hospitalized babesiosis study prior to the end of the 2025 tick season in early October, the Company’s current cash position is expected to allow the trial’s interim analysis to be conducted prior to the need for additional capital. Financial Highlights: Q2 2025 net product revenues decreased 19% year-over-year from $125 thousand to $101 thousand. This was associated with a decrease of 17% in ARAKODA pharmacy deliveries, from 1,301 boxes (Q2 2024) to 1,082 16-count box equivalents (Q2 2025). This occurred due to a temporary disruption of supply of ARAKODA 16-count boxes which was incompletely mitigated by the introduction of the new 8-count ARAKODA bottle, and importation, with FDA consent, of KODATEF (tafenoquine 16-count boxes). New commercial lots of ARAKODA 16-count boxes are anticipated to enter the supply chain in September, 2025. The Company achieved a gross profit of approximately $51 thousand in the second quarter of 2025, compared to an approximate gross profit of $35 thousand in the second quarter of 2024. This was primarily due to lower overall cost of sales and via the sale of KODATEF 16-count boxes (which had fewer discounts/rebates). Operating expenses were approximately $1.86 million in the second quarter of 2025, compared to approximately $4.22 million in the second quarter of 2024. This was primarily due to the absence of one-off, non-cash, research and development costs that occurred during the same period in...

60 Degrees Pharmaceuticals (SXTP) announced results of an insurance claims analysis related to babesiosis and chronic fatigue, as conducted by Komodo Health. Results showed approximately 25,000 Americans seek reimbursement for babesiosis-related medical costs each year, according to 60 Degrees Pharmaceuticals. In contrast, current estimates published by the Centers for Disease Control and Prevention show only 2,000 cases in 2020. Babesia infections last at least 12 months in 14 percent of patients and may relapse up to 27 months later, as documented in the scientific literature. Many physicians treating tick-borne infections speculate the true duration of infection may be much longer. The claims data indicated approximately 31 percent of babesiosis cases persist longer than 30 days, and that nearly half of those are associated with chronic fatigue lasting longer than six months. Fatigue is the last symptom of babesiosis to resolve in acute disease. Chronic fatigue during babesiosis has not been systematically described in the literature. Further, the claims data, which captured approximately 40 percent of U.S. diagnostic data, showed that over three years, more than 12 million U.S. adults experienced chronic fatigue greater than six months in duration. Current Infectious Diseases Society of America advice and other professional guidelines do not mandate babesiosis as a differential diagnosis if a patient self-reports experiencing such fatigue. The Company is testing, through its clinical development program, the medical hypothesis that the true burden of babesiosis is much larger than claims data suggest and is a function of the incidence of chronic fatigue lasting six months or longer, multiplied by the proportion of such individuals with confirmable infections. A molecular incidence study in patients with chronic fatigue commissioned by the Company was recently completed. Once published, the data will allow establishment of a ceiling on the incidence of persistent babesiosis. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SXTP: Discla...

Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand. Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2025 year, ended March 31, 2025. Financial Highlights for the Quarter Ended March 31, 2025: Net product revenues increased approximately 55% from $105.7 thousand for the first quarter of 2024 to approximately $163.6 thousand for the first quarter of 2025; the Company credits growth from domestic sales of ARAKODA®. The Company achieved a gross profit of approximately $90.3 thousand in the first quarter of 2025, compared with an approximate gross profit of $40.2 thousand in the first quarter of 2024. Operating expenses were approximately $2.09 million in the first quarter of 2025, compared with approximately $1.41 million in the first quarter of 2024. Increased expenditures in sales and investor-related services along with stock-based compensation accounted for $535.4 thousand of the increase. Net loss attributable to common shareholders in the first quarter of 2025 was approximately $2.01 million, or ($1.56) per share, compared with a net income of approximately $308.7 thousand, or $1.83 per share in the first quarter of 2024. The change in fair value of derivative liabilities accounted for $1.74 million of this difference in income attributable. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C...

In a survey representative of the general U.S. adult population, 1.26 percent of respondents – equivalent to about 3 million people – reported having received a medical diagnosis of babesiosis during their life-time; CDC data imply only about 73,000 people in that category. At the time they replied to the survey, 3.7 percent of respondents – equivalent to about 9.9 million people – reported they had been experiencing fatigue, a common symptom of babesiosis, for six months or longer. WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced findings that the actual burden of babesiosis in the United States (U.S.) may be significantly higher than Centers for Disease Control and Prevention (CDC) statistics suggest. Preliminary results of an online survey conducted by the Company showed that nearly 3 million Americans (1.26 percent of the adult population in 2020) may have received a babesiosis diagnosis from a medical practitioner in their lifetime. In contrast, CDC reports 1,834 cases of babesiosis in 2020. Even though this annual number relies on different methodologies and timeframes, and is not directly comparable to the Company’s estimates, the disparity suggests the possibility that babesiosis is significantly underdiagnosed or underreported in existing public health reporting data. The Company believes this may indicate a greater demand for effective treatment than suggested by current CDC statistics. The survey included responses from 6,000 participants selected to match the U.S. adult demographic distribution. Babesiosis is a serious, emerging tick-borne disease often found as a co-infection with Lyme disease. It may be life-threatening in immunocompromised and elderly individuals. An as yet untested medical hypothesis advanced by some prescribing physicians in the Lyme disease community is that persistent Babesia infection contributes to chronic fatigue and other problems. If this is true, millions of Americans with persistent fatigue, a common symptom of babesiosis, may be living with an undiagnosed but potentially treatable illness. The Company commissioned the survey as part of its goal to define the size of the commercial market for babesiosis treatment candidates now in...

Revenue: US$681.3k (up 169% from FY 2023). Net loss: US$7.95m (loss widened by 111% from FY 2023). US$17.48 loss per share. The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 2.4%. Earnings per share (EPS) exceeded analyst estimates by 24%. Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are up 4.0% from a week ago. It is worth noting though that we have found 5 warning signs for 60 Degrees Pharmaceuticals (4 don't sit too well with us!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

FY 2024 net product revenues increased 140% to $607.6 thousand. FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the 2024 fiscal year, ended December 31, 2024. Financial Highlights for the Fiscal Year Ended December 31, 2024: Net product revenues increased 140% from $253.6 thousand for fiscal year 2023 to $607.6 thousand for fiscal year 2024; the Company credits growth from domestic commercial sales of ARAKODA®. The Company achieved a gross profit of approximately $222.8 thousand in fiscal year 2024, compared to an approximate gross loss of $221 thousand in fiscal year 2023. Increased sales volume allowed the Company to overcome fixed cost of goods expense associated with the Drug Supply Chain Security Act that previously led to a gross loss. Operating expenses were approximately $10.0 million in fiscal year 2024, compared with approximately $4.9 million in fiscal year 2023. The increase in operating expenses was primarily due to a non-recurring non-cash Research and Development charge of $2.63 million, non-recurring non-cash delivery of research materials ($0.6 million) and Research and Development costs associated with the Company’s babesiosis clinical trial program ($1.36 million). Net loss attributable to common shareholders in calendar year 2024 was approximately $8.43 million, or $18.55 per share, compared with a net loss of approximately $3.925 million, or $59.18 per share in fiscal year 2023, representing a $4.505 million decline. This decline in profitability is mostly attributed to an increase in non-recurring non-cash Research and Development expenses of $3.23 million. Recent Business Highlights Due to a recent surge in demand for Arakoda® in the U.S. market, the Company submitted a regulatory discretion request to FDA in December 2024 to allow importation of Kodatef® (Australian-branded equivalent of Arakoda) to ensure continuous U.S. commercial supply. This was granted in February 2025, and Kodatef was made available for distribution on March 10, 2025, through a specialty pharmacy serving all 50 states. The Company is completing validation of two additional lots o...